Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980761 | 0.92 | ACE2 (0.54) | ACE2LMNAFDPSMAPTOPRM1 | |
| SCHEMBL978906 | 0.92 | ACE2 (0.48) | ACE2LMNADNM1TSHRSMN1; SMN2 | |
| SCHEMBL7781562 | 0.90 | ACE2 (0.52) | ACE2LMNADNM1FDPSOPRM1 | |
| SCHEMBL28025529 | 0.90 | ACE2 (0.57) | ACE2LMNADNM1TSHRFDPS | |
| SCHEMBL28025470 | 0.90 | ACE2 (0.57) | ACE2LMNADNM1TSHRFDPS | |
| SCHEMBL7776283 | 0.90 | ACE2 (0.52) | ACE2LMNADNM1FDPSOPRM1 | |
| SCHEMBL7782859 | 0.90 | ACE2 (0.52) | ACE2LMNADNM1FDPSOPRM1 | |
| SCHEMBL28025558 | 0.90 | ACE2 (0.57) | ACE2LMNADNM1TSHRFDPS | |
| SCHEMBL22749072 | 0.90 | ACE2 (0.57) | ACE2LMNADNM1TSHRFDPS | |
| SCHEMBL27394455 | 0.90 | ACE2 (0.57) | ACE2LMNADNM1TSHRFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023223888-A1 | METHOD FOR PRODUCING POLYCARBONATE RESIN, AND ALICYCLIC POLYCARBONATE RESIN | 旭化成株式会社 | 2023-11-23 | — | — | WO | disclosed |
| US-20230159727-A1 | STERICALLY HINDERED AMINE STABILIZER MIXTURES | BASF SE (DE) | 2023-05-25 | — | — | US | disclosed |
| EP-3935052-A1 | STERICALLY HINDERED AMINE STABILIZER MIXTURES | BASF SE (DE) | 2022-01-12 | — | — | EP | disclosed |
| CN-113544126-A | Hindered amine stabilizer mixtures | 巴斯夫欧洲公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-109721723-B | Surfactant, method for producing the same, and solution containing the same | 中日合成化学股份有限公司 | 2021-07-06 | — | — | CN | disclosed |
| WO-2020182587-A1 | STERICALLY HINDERED AMINE STABILIZER MIXTURES | BASF SE (DE) | 2020-09-17 | — | — | WO | disclosed |
| EP-3191471-B1 | 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-9944623-B2 | Sterically hindered amine stabilizer | BASF SE (DE) | 2018-04-17 | — | — | US | disclosed |
| EP-2475655-B1 | STERICALLY HINDERED AMINE STABILIZER | BASF SE (DE) | 2017-10-11 | — | — | EP | disclosed |
| EP-3191471-A1 | 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-07-19 | — | — | EP | disclosed |
| EP-1209166-A1 | NOVEL A-500359 DERIVATIVES | Sankyo Company, Limited (JP) | 2002-05-29 | — | — | EP | disclosed |
| EP-1201632-A1 | FUSED RING COMPOUND | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2002-05-02 | — | — | EP | disclosed |
| EP-0763524-B1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO CO (JP) | 2000-08-23 | — | — | EP | disclosed |
| US-6040339-A | TREATMENT AND PROPHYLAXIS OF HYPERCHOLESTEREMIA OR ARTERIOSCLEROSIS IN A MAMMAL | SANKYO COMPANY, LIMITED (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5880147-A | Amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prohylactic use | SANKYO COMPANY, LIMITED (JP) | 1999-03-09 | — | — | US | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0763524-A1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-4859759-A | Siloxane containing benzotriazolyl/tetraalkylpiperidyl substituent | KIMBERLY-CLARK CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159727-A1 | STERICALLY HINDERED AMINE STABILIZER MIXTURES | PYM1, H1-4, C5 | ACE2 2494/4885LMNA 2637/4885DNM1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.